resulting in net clinical benefit with increasingly potent oral antiplatelet regimens. In each case, as with TRITON-TIMI 38, the absolute reduction in ischemic events was greater than the increase in major bleeds, resulting in net clinical benefit with increasingly potent oral antiplatelet regimens.[...
Common Terminology Criteria for Adverse Events (CTCAE) version 4.03 2010.可见于:https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf. 超敏反应,过敏反应和过敏性休克 • 在某些方案中,门冬酰胺酶产品超敏反应发生率很高.特别值得关注的是 2 级或 2 级...